'''Xaliproden''' (codenamed '''SR57746''') is a drug which acts as a [[5-HT1A receptor|5HT<sub>1A</sub>]] [[agonist]].<ref>{{cite journal | last1 = Appert-Collin | first1 = A | last2 = Duong | first2 = FH | last3 = Passilly Degrace | first3 = P | last4 = Warter | first4 = JM | last5 = Poindron | first5 = P | last6 = Gies | first6 = JP | title = MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden | journal = International Journal of Immunopathology and Pharmacology | volume = 18 | issue = 1 | pages = 21–31 | year = 2005 | pmid = 15698508 }}</ref> It has neurotrophic and neuroprotective effects ''[[in vitro]]'',<ref>{{cite journal | last1 = Labie | first1 = C | last2 = Lafon | first2 = C | last3 = Marmouget | first3 = C | last4 = Saubusse | first4 = P | last5 = Fournier | first5 = J | last6 = Keane | first6 = PE | last7 = Le Fur | first7 = G | last8 = Soubrié | first8 = P | title = Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex | journal = [[British Journal of Pharmacology]] | volume = 127 | issue = 1 | pages = 139–44 | year = 1999 | pmid = 10369466 | pmc = 1566010 | doi = 10.1038/sj.bjp.0702545 }}</ref><ref>{{cite journal | last1 = Duong | first1 = FH | last2 = Warter | first2 = JM | last3 = Poindron | first3 = P | last4 = Passilly | first4 = P | title = Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons | journal = British Journal of Pharmacology | volume = 128 | issue = 7 | pages = 1385–92 | year = 1999 | pmid = 10602316 | pmc = 1571767 | doi = 10.1038/sj.bjp.0702910 }}</ref> and has been proposed for use in the treatment of several neurodegenerative conditions including [[amyotrophic lateral sclerosis]] (ALS)<ref>{{cite journal | last1 = Meininger | first1 = V | last2 = Bensimon | first2 = G | last3 = Bradley | first3 = WR | last4 = Brooks | first4 = B | last5 = Douillet | first5 = P | last6 = Eisen | first6 = AA | last7 = Lacomblez | first7 = L | last8 = Leigh | first8 = PN | last9 = Robberecht | first9 = W | title = Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials | journal = Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders | volume = 5 | issue = 2 | pages = 107–17 | year = 2004 | pmid = 15204012 | doi = 10.1080/14660820410019602 }}</ref> and [[Alzheimer's disease]].<ref>{{cite journal |vauthors=Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P | title = Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats
